Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of TBI-1301 in Patients With Solid Tumors
NCT02869217Phase 1Active, not recruiting
- Sponsor
- University Health Network
- Start
- Sep 2016
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-NY-ESO-1 TCR-T in solid tumor (2 cohorts), sponsored by University Health Network. Primary endpoints: Safety profile (adverse events, RCR, clonality, PK) at 8 weeks and Recommended phase 2 dose at 8 weeks. Started Sep 2016; status: active, not recruiting.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02869217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869217.